Eli lilly and company
Investor profile
Corporate
Deals
7
distinct rounds
Companies
6
backed
Active span
2023–2025
3 yrs
Total round €
€226M
sum of rounds joined
Deals by year
distinct rounds / yearTop sectors
by dealsStages
by dealsCountries
by dealsCo-investment network
shared roundsHover a node for shared-deal counts; click a co-investor to open its profile.
Frequent co-investors
shared rounds- BGF2
- Calculus Capital2
- Maven Capital Partners2
- Mercia Ventures2
- +ND Capital1
- 4BIO Capital1
- 4see Ventures1
- AdBio partners1
- Alexandria Venture Investments1
- Apollo Health Ventures1
- Athos Capital1
- Bernina BioInvest1
- Boehringer Ingelheim Venture Fund1
- British Patient Capital1
- Cambridge Enterprise1
- Cambridge Innovation Capital1
- Cystic Fibrosis Foundation1
- Dementia Discovery Fund1
- Earlybird Venture Capital1
- Eos Advisory1
- EOS Ventures1
- General Catalyst1
- JDRF T1D Fund1
- LifeArc Ventures1
- LifeLink Ventures1
Portfolio
top 30 by total round €| Company | Country | Rounds | Total € |
|---|---|---|---|
| Maxion Therapeutics | UK | 1 | €66M |
| haya therapeutics | Switzerland | 1 | €57M |
| Trimtech Therapeutics | UK | 1 | €29M |
| DiogenX | France | 1 | €28M |
| Laverock Therapeutics | UK | 2 | €23M |
| ViaNautis | UK | 1 | €23M |
Biggest deals
top 10 by amount| Company | Stage | Amount | Date |
|---|---|---|---|
| Maxion Therapeutics | Series A | €66M | 2025-03 |
| haya therapeutics | Series A | €57M | 2025-05 |
| Trimtech Therapeutics | Seed | €29M | 2025-03 |
| DiogenX | Series A | €28M | 2023-05 |
| ViaNautis | Series A | €23M | 2023-11 |
| Laverock Therapeutics | Seed | €16M | 2023-10 |
| Laverock Therapeutics | Seed | €7.6M | 2025-06 |